Atlas Trials

A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma

Clinical trial NCT05919030 · RECRUITING

Trial details

NCT number
NCT05919030
Sponsor
Renmin Hospital of Wuhan University
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Esophageal Squamous Cell Carcinoma
Start date
2023-07-01
Primary completion
2026-07-01
Enrollment
155

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.